

YKP10461

Product Name: YKP 10461

Synonyms: YKP 10461

Indication: Schizophrenia

Company: SK biopharmaceuticals

YKP 10461 (also known as SKL PD), an oral selective and reversible inhibitor of monoamine oxidase-B, for the treatment of Parkinson's disease.

YKP10461 is a new chemical entity currently under investigation for the treatment of neurological diseases. It is a novel small molecule, a non-propargyl amine that functions as a reversible and highly selective monoamine oxidase B (MAO-B) inhibitor. YKP10461 is a hydrophobic compound that is practically insoluble in water. In order to facilitate gastric absorption, a hot melt extruded drug product formulation was developed.

MAO-B has been identified in human brain tissue, and its activity increases with age (Ref 1). Inhibition of this enzyme is one of the important therapeutic strategies for the treatment of Parkinson's Disease (PD) (Ref 2). YKP10461 is being developed as a potential drug for the treatment of PD based on its biochemical action in vitro and its reduction of motor complication properties in vivo along with a favorable safety profile. In addition, preclinical studies suggest that YKP10461 may slow the progression of the disease as well as provide palliative relief of the symptoms of PD, notably dyskinesia, a limitation of current medications

SK Biopharmaceuticals commenced research and development of new drugs in 1993 as part of our search for the next-generation growth engine of SK Group. The exciting ascend of SK Biopharmaceuticals began with the acquisition of FDA approval for clinical test for a new candidate drug substance in 1996.* Investigational New Drug (IND) application: Application for approval of clinical tests on candidate substance, of which safety and efficacy have been verified in the preliminary clinical test, by testing them on human subjects Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at the Bio Science Research Institute in Pangyo Techno-valley, Gyeonggi Province. Further, SK Life Science Inc. in Fair Lawn, New Jersey, USA, is pursuing global clinical development and direct marketing. In addition, SK Bio-pharm Tech. Company, Ltd. in Shanghai, China is striving to secure opportunities for strategic alliances in the development of new drugs.